> Consegna has sold its Linguet technology to Imugene in exchange for a 29% shareholding. Article
> Intellipharmaceutics has settled all outstanding patent litigation with AstraZeneca ($AZN) over the generic version of AZ's Seroquel XR, an extended-release formulation of quetiapine. Press release
> The FDA has accepted NuPathe's ($PATH) resubmission of Zelrix, its migraine patch; the target date for the FDA to complete its review of the NDA is Jan. 17. Press release
> BioAlliance Pharma has received a U.S. patent for Sitavig, a tablet that sticks to the upper gum and delivers acyclovir to treat recurrent cold sores (labial herpes). Article
> Laser-engineered dissolving microneedles could deliver nadroparin. Abstract
> BD Medical's new needle aims to improve performance and patient comfort. Press release
> Bio-Path has started enrollment of a fourth cohort of a Phase I trial of liposomal Grb-2 for leukemia. Press release
> Diabetology to develop oral insulin for India. Press release
And Finally… Alexza's ($ALXA) CEO has high expectations of receiving FDA approval for Adasuve, its inhaled antipsychotic. Article